A randomised phase II study of Nivolumab plus Ipilimumab versus Standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

Ahrens M, Scheich S, Goekbuget N, Boleti E, Gruenwald V, Escudier B, Goebell P, Gschwend J, Hartmann A, Miller K, Burkholder I, Schmidinger M, Rey JPM, Bergmann L (2018)


Publication Type: Conference contribution

Publication year: 2018

Journal

Book Volume: 41

Pages Range: 73-73

DOI: 10.1200/jco.2020.38.15_suppl.tps5103

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Ahrens, M., Scheich, S., Goekbuget, N., Boleti, E., Gruenwald, V., Escudier, B.,... Bergmann, L. (2018). A randomised phase II study of Nivolumab plus Ipilimumab versus Standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST). (pp. 73-73).

MLA:

Ahrens, M., et al. "A randomised phase II study of Nivolumab plus Ipilimumab versus Standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)." 2018. 73-73.

BibTeX: Download